Etacrynic acid, a loop diuretic used to treat edema and hypertension, was developed in the mid-20th century and became widely used for patients who were intolerant to sulfonamide-based diuretics. Its history is marked by its effectiveness in promoting diuresis and fluid excretion, particularly in cases of congestive heart failure, liver cirrhosis, and renal impairment, while also carrying a risk of electrolyte disturbances such as hypokalemia and dehydration. Etacrynic acid acts by inhibiting the Na⁺-K⁺-2Cl⁻ symporter in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water. Its development included careful clinical evaluation to monitor for adverse effects such as ototoxicity and to establish safe dosing protocols, particularly in patients with preexisting renal or hepatic disease.
BRAND NAMES
Edecrin – the most widely recognized brand name for oral and intravenous formulations
Ecrin – available in some countries as an alternative brand.
MECHANISM OF ACTION
Etacrynic acid is a loop diuretic that exerts its pharmacological effects by inhibiting the Na⁺-K⁺-2Cl⁻ symporter in the thick ascending limb of the loop of Henle in the kidney. This inhibition prevents reabsorption of sodium, potassium, and chloride ions, leading to increased excretion of electrolytes and water, which reduces extracellular fluid volume.
PHARMACOKINETICS
Absorption
Etacrynic acid is well absorbed orally, with peak plasma concentrations typically reached within 1–2 hours after administration. Its oral bioavailability can be variable, ranging from 60% to 90%, depending on factors such as food intake and gastrointestinal motility.
Distribution
Etacrynic acid has a relatively low volume of distribution, approximately 0.1–0.2 L/kg, indicating that it is largely confined to the plasma and extracellular fluid rather than extensively penetrating body tissues.
Metabolism
Etacrynic acid undergoes limited hepatic metabolism. A portion of the drug is metabolized in the liver through conjugation reactions, forming glucuronide metabolites, which are pharmacologically inactive.
Elimination
Etacrynic acid is primarily excreted via the kidneys, with approximately 60–70% of an oral dose recovered in urine, mainly as the unchanged parent compound and a smaller fraction as glucuronide metabolites. Renal excretion occurs through glomerular filtration and tubular secretion, which accounts for its rapid onset of action and effectiveness in promoting diuresis.
PHARMACODYNAMICS
Etacrynic acid is a potent loop diuretic that produces its effects by inhibiting the Na⁺-K⁺-2Cl⁻ symporter in the thick ascending limb of the loop of Henle. This inhibition prevents the reabsorption of sodium, potassium, and chloride, leading to increased excretion of water and electrolytes, including calcium and magnesium.
ADMINISTRATION
Etacrynic acid can be administered orally or intravenously, depending on the clinical situation and the desired speed of diuresis. Oral tablets are typically used for ongoing management of edema and hypertension, while intravenous administration is preferred in acute settings, such as severe fluid overload or when rapid diuresis is required.
DOSAGE AND STRENGTH
Etacrynic acid is available in oral and intravenous formulations, with dosing individualized based on the patient’s condition, response, and renal function. Oral tablets are commonly available in 25 mg and 50 mg strengths, typically administered once to three times daily depending on severity of edema or fluid retention.
DRUG INTERACTIONS
Etacrynic acid can interact with a variety of drugs, primarily due to its potent diuretic effects and influence on electrolyte balance. Concomitant use with other antihypertensives or diuretics may increase the risk of hypotension, dehydration, and electrolyte disturbances.
FOOD INTERACTIONS
Etacrynic acid has minimal direct interactions with food, and oral administration can generally be taken with or without meals. However, foods that affect electrolyte balance, such as those high in potassium, sodium, or magnesium, may influence the drug’s effectiveness and safety.
CONTRAINDICATIONS
Etacrynic acid is contraindicated in patients with known hypersensitivity to the drug. It should not be used in individuals with anuria, severe electrolyte depletion (especially hypokalemia or hyponatremia), or hepatic coma and precoma due to the risk of worsening fluid and electrolyte imbalances.
SIDE EFFECTS
Increased urination (diuresis)
Thirst or mild dehydration
Dizziness or lightheadedness, especially on standing (orthostatic hypotension)
Gastrointestinal disturbances: nausea, vomiting, diarrhea.
OVER DOSAGE
Overdosage of etacrynic acid can occur with accidental or excessive administration, particularly withhigh oral or intravenous doses. Symptoms of overdose primarily result from excessive diuresis and electrolyte disturbances and may include severe dehydration, hypotension.
TOXICITY
Etacrynic acid toxicity primarily arises from excessive diuresis and resultant electrolyte imbalances. Overexposure can lead to severe hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia, which may cause muscle weakness, cramps, arrhythmias, or cardiac arrest in extreme cases. Rapid intravenoas administration, especially at high doses, can result in ototoxicity, manifesting as tinnitus, hearing loss, or vertigo.
